VANCOUVER, Jan. 19 /CNW/ - In keeping with its commitment to connect
industry, regulatory experts, therapeutic societies and translational
centers to advance emerging cellular therapies, ISCT announces its
first commercial development focus group addressing Cell Therapies for
Peripheral Vascular Disease (PVD).
PVD is a condition in which the arteries that carry blood to the arms or
legs become narrowed or clogged. In a primary care population defined
by age and common risk factors the prevalence of PVD is approximately
one in three1. Critical Limb Ischemia (CLI) is a very severe condition of PVD with
patients suffering severe pain and skin ulcers which can lead to limb
amputation. CLI has a 15-30% mortality rate at 5 years.2 .
To address this debilitating condition ISCT has created a progressive
forum to unite an expert panel and facilitate in depth, open discussion
of whether, and how, cell therapy can meet the unmet needs of these
patients. The focus group will take place in New York, USA January 21
2011 in partnership with the Cardiovascular Research Foundation
(www.crf.org), sponsor of the Sixth International Conference on Cell
Therapy for Cardiovascular Disease.
"As we enter the era of 300+ patient Phase 3 studies, it is crucial for
the research community to identify appropriate end points that
correlate with meaningful clinical outcomes", said Warren Sherman, MD,
Director, Regenerative Cardiovascular Research at The Jack H. Skirball
Center for Cardiovascular Research. "From there, trial design can be
optimized to assess clinical efficacy and, hopefully, improve outcomes
of patients with CLI. These patients have a very poor prognosis. To
help them with cell-based therapy would be a huge advance, and would
have implications for patients with vascular disease of other organ
Ed Horwitz, M.D. PhD, President of ISCT strongly agreed, "the launch of
this series of focus groups is the latest initiative through which ISCT
is building alignment with academia and industry to expedite the
development and maturation of the field and ultimately bring cell
therapy treatments to patients faster. It is ISCT's intent that the
international field of cell therapy and regenerative medicine will be
able to benefit from the focus groups through public open access to the
final report and outcomes as published in per reviewed journals".
Visit www.celltherapyfocusgroups.com for further information on the agenda and registration details.
The ISCT focus group initiative follows the successful launch of ISCT's
Industry Community in August 2010. See: ISCT - Media.
ISCT welcomes the following new corporate members into the Industry
Community for 2011:
Patrons: Aastrom Biosciences Inc., BD Biosciences Inc. BioLife Solutions Inc.,
Pfizer Regenerative Medicine, Pluristem Therapuetics Inc. Partners; CaridianBCT Inc., Sartorius Stedim Biotech GmbH., STEMCELL
Technologies Inc. Supporters: CellGenix GmbH., Pharmacell B.V. Members: Apceth GmbH & Co. Preservation Solutions Inc, Beike Biotechnology
Co.Ltd., DCi Biotech Inc., Tengion Inc., STEMSOFT Software Inc., ZMKS
International Cancer Therapy Biotechnology Co. Ltd.
The complete list of members can be viewed on the Industry Community
page of www.celltherapysociety.org
ISCT is a global association driving the translation of scientific
research to deliver innovative cellular therapies to patients.
Established in 1992, its membership and leadership comprises
world-class scientists, clinicians, technologists, biotech/pharma and
regulatory professionals from around the world focused on pre-clinical
and translational aspects of developing cell therapy products.
Hirsch AT et al. JAMA. 2001;286:1317-1324
Hirsch AT et al. Circulation. 2006;113:e463-654
SOURCE International Society for Cellular Therapy
For further information: